Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
Event: ESC Congress 2020
Topic: Oral Anticoagulation
Session: Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation
Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study
Event: ESC Congress 2019
Topic: Treatment
Session: Prevention of thromboembolism and atrial remodelling in atrial fibrillation
A new score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Event: ESC Congress 2018
Topic: Oral Anticoagulation
Session: Atrial fibrillation - Stroke prevention 2
ESC 365 is supported by
